期刊
LANCET ONCOLOGY
卷 15, 期 8, 页码 E327-E340出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(14)70017-8
关键词
-
类别
资金
- Astellas Pharma
- Gilead Sciences
- Merck Co
- Pfizer
- National Institute for Health Research [CS/08/08/10] Funding Source: researchfish
- National Institutes of Health Research (NIHR) [CS/08/08/10] Funding Source: National Institutes of Health Research (NIHR)
Invasive opportunistic fungal diseases (IFDs) are important causes of morbidity and mortality in paediatric patients with cancer and those who have had an allogeneic haemopoietic stem-cell transplantation (HSCT). Apart from diff erences in underlying disorders and comorbidities relative to those of adults, IFDs in infants, children, and adolescents are unique with respect to their epidemiology, the usefulness of diagnostic methods, the pharmacology and dosing of antifungal agents, and the absence of interventional phase 3 clinical trials for guidance of evidence-based decisions. To better define the state of knowledge on IFDs in paediatric patients with cancer and allogeneic HSCT and to improve IFD diagnosis, prevention, and management, the Fourth European Conference on Infections in Leukaemia (ECIL-4) in 2011 convened a group that reviewed the scientific literature on IFDs and graded the available quality of evidence according to the Infectious Diseases Society of America grading system. The final considerations and recommendations of the group are summarised in this manuscript.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据